These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 18334761)
1. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. Bakchine S; Loft H J Alzheimers Dis; 2008 Feb; 13(1):97-107. PubMed ID: 18334761 [TBL] [Abstract][Full Text] [Related]
2. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. Bakchine S; Loft H J Alzheimers Dis; 2007 Jul; 11(4):471-9. PubMed ID: 17656827 [TBL] [Abstract][Full Text] [Related]
3. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I; JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594 [TBL] [Abstract][Full Text] [Related]
4. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT; Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936 [TBL] [Abstract][Full Text] [Related]
5. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Peskind ER; Potkin SG; Pomara N; Ott BR; Graham SM; Olin JT; McDonald S Am J Geriatr Psychiatry; 2006 Aug; 14(8):704-15. PubMed ID: 16861375 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Orgogozo JM; Rigaud AS; Stöffler A; Möbius HJ; Forette F Stroke; 2002 Jul; 33(7):1834-9. PubMed ID: 12105362 [TBL] [Abstract][Full Text] [Related]
7. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial. Pomara N; Ott BR; Peskind E; Resnick EM Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274 [TBL] [Abstract][Full Text] [Related]
8. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Farlow MR; Graham SM; Alva G Drug Saf; 2008; 31(7):577-85. PubMed ID: 18558791 [TBL] [Abstract][Full Text] [Related]
9. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. Ott BR; Blake LM; Kagan E; Resnick M; J Neurol; 2007 Mar; 254(3):351-8. PubMed ID: 17345042 [TBL] [Abstract][Full Text] [Related]
10. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Mecocci P; Bladström A; Stender K Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640 [TBL] [Abstract][Full Text] [Related]
11. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. Dysken MW; Sano M; Asthana S; Vertrees JE; Pallaki M; Llorente M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Zachariah S; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Segal Y; Peduzzi PN; Guarino PD JAMA; 2014 Jan; 311(1):33-44. PubMed ID: 24381967 [TBL] [Abstract][Full Text] [Related]
12. [Mémantine (Ebixa): a new therapeutic strategy for the treatment of moderate to severe forms of Alzheimer's disease]. Gallarda T; Lôo H Encephale; 2004; 30(1):69-79. PubMed ID: 15029079 [TBL] [Abstract][Full Text] [Related]
13. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. van Dyck CH; Tariot PN; Meyers B; Malca Resnick E; Alzheimer Dis Assoc Disord; 2007; 21(2):136-43. PubMed ID: 17545739 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Nakamura Y; Kitamura S; Homma A; Shiosakai K; Matsui D Expert Opin Pharmacother; 2014 May; 15(7):913-25. PubMed ID: 24673497 [TBL] [Abstract][Full Text] [Related]
16. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease. Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of memantine in the treatment of dementia. Rossom R; Adityanjee ; Dysken M Am J Geriatr Pharmacother; 2004 Dec; 2(4):303-12. PubMed ID: 15903287 [TBL] [Abstract][Full Text] [Related]
18. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors. Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687 [TBL] [Abstract][Full Text] [Related]
19. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension. Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421 [TBL] [Abstract][Full Text] [Related]
20. Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease. Emre M; Mecocci P; Stender K J Alzheimers Dis; 2008 Jun; 14(2):193-9. PubMed ID: 18560130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]